Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy
Zenghui Li, Yuqing Feng, Hong Han, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 24
Closed Access | Times Cited: 15

Showing 15 citing articles:

Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models
Guillaume Dutheuil, Killian Oukoloff, Julien Korac, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Effects of 131I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer
Liguo Yang, Zhigang Yang, Jun Zhang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 1, pp. 42-58
Closed Access
METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination
Zhuonan Liu, Tianshui Sun, Zhe Zhang, et al.
Clinical and Translational Medicine (2025) Vol. 15, Iss. 2
Open Access
The role of m6A modification during macrophage metabolic reprogramming in human diseases and animal models
Huiling Wang, Peiqi Xu, Kai Yin, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
METTL3 suppressing SLC31A1 m6A modification regulates trophoblast migration and invasion
Song Wang, Yixiong Lin, Qiong Deng, et al.
Placenta (2025) Vol. 164, pp. 21-30
Closed Access
Main methods and tools for peptide development based on protein-protein interactions (PPIs).
Javiera Baeza, Mauricio Bedoya, Pablo Cruz, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151623-151623
Closed Access
Recent Advances in Medicinal Chemistry Strategies for the Development of METTL3 Inhibitors
G. Li, Wei Chen, Dan Liu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117560-117560
Closed Access
METTL Family in Healthy and Disease
Jiejie He, Fengchen Hao, Shiqi Song, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 3
Regulatory effect of N6-methyladenosine on tumor angiogenesis
Yuyan, Enwu Yuan
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Stabilization of RRBP1 mRNA via an m6A-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3
Yuqing Feng, Zenghui Li, Jinwei Zhu, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access
RNA modification in normal hematopoiesis and hematologic malignancies
Xi Chen, Yixiao Yuan, Fan Zhou, et al.
MedComm (2024) Vol. 5, Iss. 11
Open Access
mRNA m6A detection
Sharon Moshitch-Moshkovitz, Michal Sevilla-Sharon, Reut Ashwal-Fluss, et al.
Nature Reviews Methods Primers (2024) Vol. 4, Iss. 1
Closed Access
Role of Peptides in Oral Cancer
Aparna Ramachandran, B. Saravanan, Debashish Dhar, et al.
(2024), pp. 133-147
Closed Access
Page 1

Scroll to top